What BIOINNOVO does

Bioinnovo S.A. is an Argentine technology-based public-private company that develops and commercializes recombinant subunit vaccines and antibody-based biologics for animal health, primarily targeting bovine viral diarrhea virus (BVDV) and neonatal calf diarrhea. Founded in 2017 through a partnership between the National Institute of Agricultural Technology (INTA) and veterinary pharmaceutical firm Vetanco S.A., the company operates from INTA's Castelar research campus in Hurlingham, Buenos Aires, and was the first entity created under Argentina's Science Technology and Innovation Act 25.467. Its 8-person team leverages INTA's CICVyA infrastructure, the INCUINTA incubation platform, and CONICET researchers to translate academic science into commercial veterinary products.

The company's core technology platform centers on the proprietary APCH1 antigen-presenting cell targeting molecule (protected under PCT/ES2008/070053), which directs viral antigens to immune system cells and reportedly produces 30-50x stronger immune responses than conventional inactivated vaccines. Its commercial product portfolio includes Vedevax BLOCK (the world's first targeted subunit recombinant BVDV vaccine, launched in 2018), Vedevax DUO (bivalent BVDV and BoHV-1 vaccine approved in 2025), Bioinnovo IgY DNT (egg-yolk-derived polyclonal antibodies for neonatal calf diarrhea, launched 2017), and a pipeline spanning VLP-based norovirus and foot-and-mouth disease vaccines plus three new SENASA submissions slated for 2026. Patent-protected IP extends through exclusive international rights to Algenex's APCH molecule for animal health.

Bioinnovo generates revenue primarily through one-time vaccine product sales (approximately 2 million doses of Vedevax BLOCK annually) and specialized diagnostic and research services, distributed almost entirely through co-founder Vetanco S.A.'s established veterinary pharmaceutical network in Argentina with regional distributors (e.g., Drovet) handling international markets. Pricing is not publicly disclosed. Customers are predominantly beef and dairy cattle producers and the veterinarians serving them, with field trials and commercial deployments documented across multiple Argentine provinces and, as of 2025, in Peru. The sole disclosed capital infusion beyond founder equity is a 2020 Argentine Ministry of Productive Development grant of ARS 10.4 million directed at scaling Vedevax BLOCK production.

Name

BIOINNOVO

Legal name

Bioinnovo S.A.

Website

https://bioinnovo.com.ar

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

BIOINNOVO S.A. is an Argentine public-private biotechnology company that develops and commercializes recombinant subunit vaccines and IgY antibody products — primarily Vedevax BLOCK and Bioinnovo IgY DNT — for beef and dairy cattle producers, leveraging INTA's research infrastructure and Vetanco S.A.'s distribution network.

Ownership category

akta.pro rank

Product category

Animal Health / Veterinary Biologicals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)

Keywords

• Recombinant subunit vaccines
• Animal health biotechnology
• Bovine viral diarrhea vaccines
• IgY antibody products
• Veterinary biological products

Headquarters

HQ city

Hurlingham

HQ country

Argentina

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Vaccine Product Sales: Sale of recombinant subunit vaccines including Vedevax BLOCK for bovine viral diarrhea control. Currently commercializing approximately 2 million doses annually, with expansion plans targeting Mercosur's 100 million breeding female cattle market.
2. Specialized Services: Provision of specialized diagnostic and research services for animal health, leveraging INTA infrastructure and expertise.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

BIOINNOVO develops and manufactures recombinant subunit veterinary vaccines and IgY antibody-based biological products for livestock disease prevention and control. Its flagship product, vedevax BLOCK, is the world's first targeted subunit recombinant vaccine against Bovine Viral Diarrhea Virus (BVDV), and the portfolio also includes BIOINNOVO IgY DNT for neonatal calf diarrhea and the bivalent vedevax DUO vaccine. The company leverages proprietary APCH1 antigen-targeting technology and operates within INTA's research infrastructure in Argentina.

Product overview

Bioinnovo is a technology-based company that develops innovative products for the agricultural and animal health sectors. Its portfolio includes two main commercial products: vedevax BLOCK (and its variants vedevax DUO and Vedevax Doble Viral BLOCK), the world's first recombinant subunit targeted vaccines for Bovine Viral Diarrhea Virus, and BIOINNOVO IgY DNT, an IgY antibody treatment for neonatal calf diarrhea. All products are developed using proprietary technology platforms including the APCH targeting molecule for vaccines and IgY production in eggs for antibodies.

Differentiator

Problem solved

Functional benefit

Brands

• VEDEVAX BLOCK: First targeted subunit recombinant vaccine against Bovine Viral Diarrhea Virus (BVDV), launched in 2018
• VEDEVAX DUO
• Bioinnovo Terneros (IgY DNT)
• SEP

Products and services

• vedevax BLOCK Targeted subunit recombinant vaccine against Bovine Viral Diarrhea Virus for cattle producers and veterinarians, delivering 12-month protection and stronger immune response than conventional inactivated vaccines.
• BIOINNOVO IgY DNT (Bioinnovo Terneros) Biological IgY antibody-based treatment for prevention and therapy of neonatal calf diarrhea, the first product developed by Bioinnovo for dairy and beef calf producers.
• vedevax DUO Bivalent recombinant subunit vaccine targeting both Bovine Viral Diarrhea Virus and Bovine Herpesvirus Type 1, expanding the vedevax line for cattle producers and veterinarians.
• Vedevax Doble Viral BLOCK Bivalent recombinant subunit vaccine against Bovine Viral Diarrhea Virus and Bovine Herpesvirus Type 1 developed using the APCH1 targeting platform and presented at scientific forums as part of the vedevax family.
• SEP (PES) Veterinary product offered by Bioinnovo within its animal health product menu, with limited publicly available detail.

Quantifiable outcome

• Abortion rate reduction from 30% to 22% (27% decrease)
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core, strategic and minor.

• INTA (Instituto Nacional de Tecnología Agropecuaria)coreStrategic or Co-development Partner · 1 January 2008Co-founding partner and parent research institution. INTA provides research infrastructure, scientific personnel through INCUINTA platform, and access to CICVyA facilities. Bioinnovo is the first company established under Argentina's Science Technology and Innovation Act 25.467.
• Vetanco S.A.coreChannel Partner/ Reseller/ Distributor · 1 January 2008Co-founding private veterinary pharmaceutical company serving as primary distributor for all Bioinnovo products in Argentina. Provides commercial network, market access, and sales infrastructure for product commercialization.
• AlgenexstrategicTechnology or IntegrationSpanish recombinant technology company providing baculovirus-based expression platforms (CrisBio and TopBac). Bioinnovo holds international rights to use Algenex's APCH molecule for animal health applications. Algenex inaugurated new production facility with capacity of 3.5 kg recombinant protein per year.
• National Research Council of Canada (NRCC)strategicStrategic or Co-development PartnerCollaborative partnership for development of innovative foot and mouth disease vaccine. Project won Empretec BNA 2024 award recognition among 1,500 applicants.
• CONICETcoreStrategic or Co-development PartnerArgentina's National Scientific and Technical Research Council providing researchers and scientific framework. Multiple CONICET researchers work within INCUINTA and Bioinnovo projects, including Dr. Andrés Wigdorovitz as Superior Researcher.
• INCUINTA PlatformcoreStrategic or Co-development PartnerINTA's technical-organizational platform for technology project development. Functions as incubation interface between research and industrial-scale manufacturing, supporting product development, scaling, and registration processes.
• German Federal Ministry of Food and Agriculture (BMEL)minorOthersGerman government ministry visited Bioinnovo as part of Argentine-German Dialogue on Sustainable Agriculture project. Discussed biotechnology, gene editing, and climate change adaptation topics.
• ANLIS-Malbrán (Instituto Nacional de Enfermedades Infecciosas)strategicStrategic or Co-development PartnerNational institute for infectious disease research collaborating on COVID-19 antibody development project including IgY and nanobody development for therapeutic applications.
• Universidad de Buenos Aires - Facultad de Ciencias Exactas y NaturalesstrategicStrategic or Co-development PartnerLeading research university part of anti-COVID-19 consortium contributing to nanobody and IgY development project for diagnosis and treatment.
• Biogénesis BagóstrategicStrategic or Co-development PartnerCollaboration on foot and mouth disease vaccine development presented at ISV 2021 Congress, combining complementary vaccine development capabilities.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Biogénesis Bagó: Argentine veterinary vaccine manufacturer, particularly strong in foot-and-mouth disease vaccines and a known Bioinnovo collaboration partner. Directly comparable as a Latin American animal health biologics company targeting the same cattle producers.
• Vetanco S.A. Argentine veterinary pharmaceutical laboratory and Bioinnovo's co-founding partner/primary distributor. Comparable as an Argentine livestock health products company, though overlapping rather than directly competitive given the distribution relationship.

Broad incumbents

• Phibro Animal Health: Global animal health and nutrition company with livestock vaccine and pharmaceutical offerings. Overlaps with Bioinnovo in serving global cattle producers, though via broader product portfolios.
• Zoetis: The world's largest animal health company with a broad livestock vaccine portfolio including BVDV products. Competes with Bioinnovo for the same cattle-producer customers globally but with much broader species coverage.
• Ceva Santé Animale: Major French veterinary pharmaceutical company with significant presence in Latin American livestock vaccines and BVDV control programs. Comparable as a multi-species animal health vaccine developer.
• Boehringer Ingelheim Animal Health: Global animal health leader with established BVDV vaccine franchises (e.g., Bovela) and significant livestock biologic R&D. Overlaps with Bioinnovo's targeted vaccine approach but with vastly greater scale.
• Elanco Animal Health: Major US-based animal health company with established livestock vaccine franchises including BVDV and bovine respiratory disease products. Comparable in target customer (cattle producers) and disease focus.

Regional players

• Tecnovax: Argentine veterinary biologics manufacturer focused on livestock vaccines, particularly in Mercosur markets. Direct comparable as a regional animal health vaccine producer targeting similar cattle producers.

Emerging players

• Algenex: Spanish recombinant technology company providing the baculovirus-based expression platforms (CrisBio, TopBac) that Bioinnovo uses in its APCH1 vaccines. Comparable as a biotech platform company in the veterinary biologics space, with direct technology partnership overlap.
• Indian Immunologicals: Indian veterinary vaccine manufacturer with livestock and companion animal portfolios, particularly active in emerging markets. Comparable as a biotech-focused veterinary vaccine producer leveraging public-sector research partnerships.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bioinnovo

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOINNOVO